BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 36369821)

  • 1. Adherence to quality indicators in chronic myeloid leukemia care: results from a population-based study in The Netherlands.
    Ector GICG; Geelen IGP; Dinmohamed AG; Hoogendoorn M; Westerweel PE; Hermens RPMG; Blijlevens NMA
    Leuk Lymphoma; 2023 Feb; 64(2):424-432. PubMed ID: 36369821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The potential health gain and cost savings of improving adherence in chronic myeloid leukemia.
    Ector GICG; Govers TM; Westerweel PE; Grutters JPC; Blijlevens NMA
    Leuk Lymphoma; 2019 Jun; 60(6):1485-1492. PubMed ID: 30668187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suboptimal care for chronic pancreatitis patients revealed by moderate to low adherence to the United European Gastroenterology evidence-based guidelines (HaPanEU): A Netherlands nationwide analysis.
    de Rijk FE; Kempeneers MA; Bruno MJ; Besselink MG; van Goor H; Boermeester MA; van Geenen EJ; van Hooft JE; van Santvoort HC; Verdonk RC;
    United European Gastroenterol J; 2020 Aug; 8(7):764-774. PubMed ID: 32588790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.
    Abbott BL
    Clin Ther; 2012 Feb; 34(2):272-81. PubMed ID: 22285209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment patterns and prognostic indicators of response to therapy among patients with chronic myeloid leukemia in Australia, Canada, and South Korea.
    Whiteley J; Iyer S; Candrilli SD; Kaye JA
    Curr Med Res Opin; 2015 Feb; 31(2):299-314. PubMed ID: 25427232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidemiology of chronic myeloid leukaemia (CML).
    Rohrbacher M; Hasford J
    Best Pract Res Clin Haematol; 2009 Sep; 22(3):295-302. PubMed ID: 19959081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of chronic myeloid leukemia and patient survival: results of five French population-based cancer registries 1980-2009.
    Penot A; Preux PM; Le Guyader S; Collignon A; Herry A; Dufour V; Monnereau A; Woronoff AS; Troussard X; Pons E; Bordessoule D; Maynadié M
    Leuk Lymphoma; 2015 Jun; 56(6):1771-7. PubMed ID: 25535815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Omitting cytogenetic assessment from routine treatment response monitoring in chronic myeloid leukemia is safe.
    Geelen IGP; Thielen N; Janssen JJWM; Hoogendoorn M; Roosma TJA; Valk PJM; Visser O; Cornelissen JJ; Westerweel PE
    Eur J Haematol; 2018 Apr; 100(4):367-371. PubMed ID: 29288559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic myeloid leukemia in the Netherlands: a population-based study on incidence, treatment, and survival in 3585 patients from 1989 to 2012.
    Thielen N; Visser O; Ossenkoppele G; Janssen J
    Eur J Haematol; 2016 Aug; 97(2):145-54. PubMed ID: 26519944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment outcome in a population-based, 'real-world' cohort of patients with chronic myeloid leukemia.
    Geelen IGP; Thielen N; Janssen JJWM; Hoogendoorn M; Roosma TJA; Willemsen SP; Visser O; Cornelissen JJ; Westerweel PE
    Haematologica; 2017 Nov; 102(11):1842-1849. PubMed ID: 28860339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia.
    Naqvi K; Jabbour E; Skinner J; Anderson K; Dellasala S; Yilmaz M; Ferrajoli A; Bose P; Thompson P; Alvarado Y; Jain N; Takahashi K; Burger J; Estrov Z; Borthakur G; Pemmaraju N; Paul S; Cortes J; Kantarjian HM
    Cancer; 2020 Jan; 126(1):67-75. PubMed ID: 31553487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Barriers to physician adherence to evidence-based monitoring guidelines in chronic myelogenous leukemia.
    Goldberg SL; Akard LP; Dugan MJ; Faderl S; Pecora AL
    J Oncol Pract; 2015 May; 11(3):e398-404. PubMed ID: 25758446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Incidence of chronic myeloid leukemia in 6 regions of Russia according to the data of the 2009-2012 population-based study].
    Kulikov SM; Vinogradova OIu; Chelysheva EIu; Tishchenko IA; Galaĭko MA; Lazareva OV; Senderova OM; Pepeliaeva VM; Meresiĭ SV; Luchinin AS; Ovsepian VA; Miliutina GI; Gavrilova LV; Avdeeva LB; Neverova AL; Turkina AG
    Ter Arkh; 2014; 86(7):24-30. PubMed ID: 25314774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicenter retrospective evaluation of Chronic Myeloid Leukemia (CML) therapy in Austria assessing the impact of early treatment response on patient outcomes in a real-life setting : R-EFECT study.
    Petzer AL; Sperr WR; Buxhofer-Ausch V; Sliwa T; Schmidt S; Greil R; Wölfler A; Pichler P; Dormann C; Burgstaller S; Tinchon C; Lang A; Goebel F; Uthman S; Muenchmeier N; Valent P
    Wien Klin Wochenschr; 2020 Aug; 132(15-16):415-422. PubMed ID: 32533444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic myeloid leukemia in 2007.
    Sessions J
    Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S4-9. PubMed ID: 18056931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Asymptomatic chronic-phase chronic myeloid leukemia BCR-ABL. (+) without splenomegaly: A case report.
    Rajabto W; Angkasa YK
    Niger J Clin Pract; 2022 Mar; 25(3):373-375. PubMed ID: 35295063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring.
    Jabbour E; Kantarjian H
    Am J Hematol; 2022 Sep; 97(9):1236-1256. PubMed ID: 35751859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting outcomes in patients with chronic myeloid leukemia at any time during tyrosine kinase inhibitor therapy.
    Quintás-Cardama A; Choi S; Kantarjian H; Jabbour E; Huang X; Cortes J
    Clin Lymphoma Myeloma Leuk; 2014 Aug; 14(4):327-334.e8. PubMed ID: 24594142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluorescent In Situ Hybridization Monitoring and Effect of Detected Early Responses in the Outcome of Patients With Chronic Phase Chronic Myeloid Leukemia: A Report From a Latin American Country.
    Bourlon C; Hernandez-Mata C; Vargas-Serafín C; Bourlon MT; Tuna-Aguilar E; Aguayo A
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16(8):453-9. PubMed ID: 27259590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of creatine kinase elevation with clinical outcomes in chronic myeloid leukemia: a retrospective cohort study.
    Bankar A; Lipton JH
    Leuk Lymphoma; 2022 Jan; 63(1):179-188. PubMed ID: 34493150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.